Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC nominations

This article was originally published in The Tan Sheet

Executive Summary

Nominations for a non-voting industry representative to serve on the Nonprescription Drugs Advisory Committee must be received by FDA no later than Dec. 15, the agency announces in the Nov. 15 Federal Register. Industry organizations interested in participating in the member's selection should notify FDA by letter. The agency will compile a list of nominees by Dec. 15 and will forward the list to participating organizations. A candidate must be selected by participants within 60 days of receipt of the FDA letter. If no candidate is chosen, the FDA commissioner will select the non-voting member, FDA notes. Self-nominations are acceptable and organizations may submit multiple nominations...

You may also be interested in...



CHPA NDAC nomination

CHPA nominates George Goldstein, MD, to represent the industry on FDA's Nonprescription Drugs Advisory Committee, the organization states in a Nov. 28 letter to FDA. The Consumer Healthcare Products Association polled members to identify Goldstein as the "consensus candidate" for industry representative. Goldstein comes to the table with a resume that includes 14 years in private practice as a pediatrician and 15 years with Sterling Drug, according to CHPA. Goldstein served as Chief Medical Officer for Sterling's OTC division, Glenbrook Labs, as well as for the Rx division, Winthrop Labs. FDA announced in November that it was taking nominations for a non-voting industry representative to serve on the committee ("The Tan Sheet" Nov. 21, 2005, In Brief)...

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Topics

UsernamePublicRestriction

Register

PS098847

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel